Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations

References

• Mixed reviews for new AML drugs. Cancer Discov 2019;9(2):OF1.
   Google Scholar
• Swoboda DM, Ali NA, Chan O, et al. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021;35(1):286–288. doi:10.1038/s41375-020-01083-3
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. Nccn guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Cancer Network. 2021;19(1):16–27. doi:10.6004/jnccn.2021.0002
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689.
   PubMed Web of Science ®Google Scholar
• Khan AQ, Kuttikrishnan S, Siveen KS, et al. RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol. 2019;54:1–13. doi:10.1016/j.semcancer.2018.03.001
   PubMed Web of Science ®Google Scholar
• Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281–298. doi:10.1038/nrm3979
   PubMed Web of Science ®Google Scholar
• Alfayez M, Issa GC, Patel KP, et al. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021;35(3):691–700. doi:10.1038/s41375-020-0920-z
   PubMed Web of Science ®Google Scholar
• Rehman AU, Rafiq H, Rahman MU, et al. Gain-of-function SHP2 E76Q mutant rescuing autoinhibition mechanism associated with juvenile myelomonocytic leukemia. J Chem Inf Model. 2019;59(7):3229–3239. doi:10.1021/acs.jcim.9b00353
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64(24):8816–8820. doi:10.1158/0008-5472.CAN-04-1923
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Martinelli S, Stella L, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. The American Journal of Human Genetics. 2006;78(2):279–290. doi:10.1086/499925
   PubMed Web of Science ®Google Scholar
• Shigemura T, Matsuda K, Kurata T, et al. Essential role ofPTPN11mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia. Br J Haematol. 2019;187(2):163–173. doi:10.1111/bjh.16060
   PubMed Web of Science ®Google Scholar
• Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure. 1998;6(3):249–254. doi:10.1016/S0969-2126(98)00027-6
   PubMed Web of Science ®Google Scholar
• Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92(4):441–450. doi:10.1016/S0092-8674(00)80938-1
   PubMed Web of Science ®Google Scholar
• Lorca R, Pannone L, Cuesta-Llavona E, et al. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders. Clin Genet. 2021;99(3):457–461. doi:10.1111/cge.13904
   PubMed Web of Science ®Google Scholar
• Shenoy RD, Yeshvanth SK, Prasada LH, et al. Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: noonan syndrome with c.218C>T mutation in PTPN11 gene. Pediatr Blood Cancer. 2019;66(2):e27527. doi:10.1002/pbc.27527
   PubMed Web of Science ®Google Scholar
• Nathany S, Chatterjee G, Ghai S, et al. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)—A real-world context. Int J Lab Hematol. 2021;43(6):1531–1538. doi:10.1111/ijlh.13680
   PubMed Web of Science ®Google Scholar
• Wang RR, Ma Y, Du S, et al. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics. Comput Biol Chem. 2019;78():133–143. doi:10.1016/j.compbiolchem.2018.10.013
   PubMed Web of Science ®Google Scholar
• Lipka DB, Witte T, Toth R, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun. 2017;8(1):2126. doi:10.1038/s41467-017-02177-w
   PubMedGoogle Scholar
• Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325–2331. doi:10.1182/blood-2003-09-3287
   PubMed Web of Science ®Google Scholar
• Castagna J, Clerc J, Dupond AS, et al. Tumeurs à cellules granuleuses multiples chez un enfant atteint d’un syndrome de Noonan compliqué de leucémie myélomonocytaire juvénile. Annales de Dermatologie et de Vénéréologie. 2017;144(11):705–711. doi:10.1016/j.annder.2017.06.008
   PubMedGoogle Scholar
• Rehman AU, Rahman MU, Khan MT, et al. The landscape of protein tyrosine phosphatase (Shp2) and cancer. Curr Pharm Des. 2019;24(32):3767–3777. doi:10.2174/1381612824666181106100837
   Web of Science ®Google Scholar
• Xu X, Cai W, Cai P, et al. Prognostic nomogram for acute myeloid leukemia patients with biallelic CEBPA mutations. Front Oncol. 2021;11:628248. doi:10.3389/fonc.2021.628248
   PubMed Web of Science ®Google Scholar
• Dos Santos-Bueno FV, Andrade FG, Sardou-Cezar I, et al. Childhood myeloid neoplasms with PTPN11 mutations in Brazil. Clin Lymphoma Myeloma Leuk. 2020;20(8):e496–e505. doi:10.1016/j.clml.2020.04.009
   PubMed Web of Science ®Google Scholar
• de Noronha TR, Mitne-Neto M, Chauffaille ML. Mutational profiling of acute myeloid leukemia with Normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification. J Invest Med. 2017;65(8):1155–1158. doi:10.1136/jim-2017-000566
   PubMed Web of Science ®Google Scholar
• Andrade FG, Noronha EP, Brisson GD, Dos Santos Vicente Bueno F, Cezar IS, Terra-Granado E et al. Molecular characterization of pediatric acute myeloid leukemia: results of a multicentric study in Brazil. Arch Med Res 2016;47(8):656-667. doi:10.1016/j.arcmed.2016.11.015
   PubMed Web of Science ®Google Scholar
• Stasik S, Eckardt JN, Kramer M, et al. Impact ofPTPN11mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Advances. 2021;5(17):3279–3289. doi:10.1182/bloodadvances.2021004631
   PubMed Web of Science ®Google Scholar
• Tavor S, Shalit T, Chapal Ilani N, et al. Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature. Haematologica. 2020;105(12):2795–2804. doi:10.3324/haematol.2019.240705
   PubMed Web of Science ®Google Scholar
• Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61. doi:10.1186/s13045-017-0431-1
   PubMedGoogle Scholar
• Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024–3032. doi:10.1182/blood-2009-01-197871
   PubMed Web of Science ®Google Scholar
• Fobare S, Kohlschmidt J, Ozer HG, et al. Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance). Blood Adv. 2021.
   Web of Science ®Google Scholar